Lilly Reports Fourth-Quarter and Full-Year 2012 Results, Revises 2013 EPS Guidance

  INDIANAPOLIS, Jan. 29, 2013 /PRNewswire/ -- Fourth quarter revenue declined 1 percent driven by Zyprexa patent expiration, largely offset by growth in other products. Fourth quarter earnings per share were $0.74 (reported), or $0.85...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news